Providing Targeted Cancer Diagnostics
-
A new division providing centralized laboratory testing, supporting Clinical Trials, Pharma and Biotech activities
-
Genetically defined human genomic reference standards (gDNA & FFPE)
-
Validated Image Analysis for accurate biomarker quantification.
-
Complete Digital Pathology for remote Case Review, Teaching & Research Pathology
-
Now performing Lymphoma, HER2 FISH/DDISH, ALK NSCLC & Bladder Cancer FISH
-
Specialist Breast & Gastric HER2 IHC testing services now available
-
Providing accredited IHC, ISH, Molecular & Digital Pathology services throughout the UK and overseas
-
Cutting edge research in Next Generation Sequencing for personalised medicine applications
-
Highly Sensitive Mutation Analysis Service for EGFR, KRAS & BRAF
Latest News
11/05/13 New Sarah Cannon/UCL-AD Molecular Profiling Laboratory Opens
A new genetic profiling laboratory set up by Sarah Cannon and UCL-AD opens, providing access to next generation molecular profiling for cancer patients across the UK. As seen on ITV Health News. Read more...
28/01/13 UCL-AD Validates New ALK IHC Assay for NSCLC
UCL-AD validates the new Roche Tissue Diagnostics ALK IHC assay for use in Non Small Cell Lung Cancer (NSCLC) patients for whom Crizotinib (Xalkori, Pfizer) is being considered. Read more...
24/10/12 UCL-AD Begins Centralised Testing for Major Clinical Trial.
Now open for recruitment, OPTIMA is a partially-blind randomised trial designed to compare clinical and economic outcomes of standard chemotherapy treatment with biomarker-directed allocation to chemotherapy or no chemotherapy in women with ER positive, HER2 negative breast cancer and either axillary node involvement or larger tumours'. Read more...
14/06/12 Fully Funded BRAF Testing Available for ALL NHS Patients Across ALL Cancer Types.
UCL-AD is pleased to announce a new free of charge BRAF mutation analysis service. Funding is now in place to test ALL NHS patients across ALL cancer types for the BRAF V600 family of mutations, specifically V600 E, D & K. Read more...
12/06/12 Fully Funded KRAS Testing for ALL NHS Colorectal Cancer Patients
UCL-AD now offers a Merck Serono funded KRAS testing service for ALL NHS patients diagnosed with colorectal cancer. Identifying patients with wild-type KRAS mCRC, who may benefit from a tretament regimen including Erbitux (Cetuximab). Read more...
12/06/12 New FDA Approved ALK Gene Rearrangement Test Available for NSCLC Patients
UCL-AD now performs the Abbott Molecular ALK Break-apart FISH assay for determination of suitability for NSCLC patients for a treatment regimen including Crizotinib. Read more...
22/05/12 UCL-AD Attends Parliamentary Briefing on Targeted Cancer Diagnostics & Personalised Medicine
Representatives from UCL-AD/London Cancer & BCUK attend parliamentary briefing to discuss the importance of targeted testing and personalised medicine, with a specific focus on colorectal cancer, KRAS testing and Cetuximab. Read more...
22/05/12 UCL-AD Supports use of new Roche HER2 Teaching Resource
Roche unveil new HER2 teaching resource. The 'HER2testing' web resource supports interpretation of HER2 testing in breast and gastric cancer in all areas including IHC, CISH, FISH and DDISH and provides a valuable resource for scientists and pathologists. Read more...
22/05/12 New Genetic Reference Standards available from HorizonDx via UCL-AD
Genetically characterized X-MAN reference standards available to support discovery, development and routine molecular testing. X-MAN reference standards are genetically defined standards enabling accurate technology benchmarking for pharmaceutical and diagnostic development. Read more...
22/05/12 UCL-AD Adopts Roche Companion Diagnostics Testing Platform
UCL-AD has chosen to adopt Roche Pathway HER2 (4B5) and Inform HER2 DDISH on the Benchmark ULTRA automated staining system for use in breast and gastric cancer HER2 testing applications. Read more...